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Abstract  
The P2Y11 receptor is a G protein-coupled receptor that is stimulated by endogenous purine 
nucleotides, particularly ATP. Amongst P2Y receptors it has several unique properties; 1) it is the 
only human P2Y receptor gene that contains an intron in the coding sequence; 2) the gene does not 
appear to be present in the rodent genome; 3) it couples to stimulation of both phospholipase C and 
adenylyl cyclase. Its absence in mice and rats, along with a limited range of selective 
pharmacological tools, has hampered the development of our knowledge and understanding of its 
properties and functions. Nonetheless, through a combination of careful use of the available tools, 
suppression of receptor expression using siRNA and genetic screening for SNPs, possible functions 
of native P2Y11 receptors have been identified in a variety of human cells and tissues. Many are in 
blood cells involved in inflammatory responses, consistent with extracellular ATP being a damage-
associated signalling molecule in the immune system. Thus proposed potential therapeutic 
applications relate, in the main, to modulation of acute and chronic inflammatory responses. 
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1. Introduction 
P2Y receptors are G protein-coupled receptors (GPCR) that are stimulated by the endogenous 
nucleotides, adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP), uridine 5'-
triphosphate (UTP), uridine 5'diphosphate (UDP) and UDP-glucose. Eight human subtypes have 
been cloned (P2Y1,2,4,6,11,12,13,14) [1,2] and are expressed throughout the body [3-5]. The missing 
numbers represent non-mammalian orthologues or proteins proposed to be P2Y receptors, but at 
which the nucleotides were subsequently found to be inactive. The eight genuine P2Y subtypes 
show differential sensitivities to the endogenous agonists and the P2Y11 receptor is activated by 
ATP and ADP, but not the uridine nucleotides. In addition, the P2Y11 receptor has several unique 
properties; 1) it is the only human P2Y receptor gene that contains an intron in the coding sequence; 
2) the gene does not appear to be present in the rodent genome; 3) it couples to stimulation of both 
phospholipase C (PLC) and adenylyl cyclase. Here, we will discuss these properties and review the 
pharmacological profile and possible physiological functions of the P2Y11 receptor.  
 
2. Cloning and sequence of P2Y11 receptors 
Humans The human P2Y11 (hP2Y11) receptor was first cloned from placenta using probes based 
on the nucleotide sequence of the P2Y4 receptor [6]. The P2RY11 gene (AJ298334) is on 
chromosome 19 (19p13.2) in humans, is 1125 base pairs long and codes a protein of 274 amino 
acids (CAC29362.1) [7]. Unlike all other P2Y subtypes, the gene has a 1.9 kb intron that separates 
two exons, which encode the first six amino acids and the rest of the receptor respectively. The 
P2Y11 protein has relatively low sequence identity with the other P2Y subtypes, ranging from 23% 
(P2Y14) to 34% (P2Y6) (Table 1).  Multiple single nucleotide polymorphisms (SNPs) have been 
identified in the human genome and two of these, rs3745601 and rs2305795, will be discussed 
below when considering possible functions of P2Y11 receptors.  
 Initially, the P2RY11 receptor sequence was reported to comprise 1113 base pairs 
(AF030335), coding 371 amino acids (AAB88674.1), but subsequently, the same group reported 
that this cDNA sequence arose from intergenic splicing of the P2RY11 gene and that of PPAN, the 
human orthologue of Ssf1, a nuclear protein that is involved in mating in Saccharomyces cerevisiae, 
which lies adjacent and upstream [7,8]. The first P2RY11 exon was thus revealed to code for the 
protein sequence MAANVS, rather than MDR, as initially reported. The P2RY11/PPAN fusion 
transcript (AJ300588) lacks the first exon of P2RY11 and the last two thirds of the final exon in 
PPAN and is of unknown function. It appears to be expressed widely throughout the body and, as 
will be discussed below, this has been a problem when studying the distribution of P2RY11 mRNA. 
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Species orthologues The canine P2RY11 receptor (NM_001204441) was subsequently cloned 
[9]. The gene is found in the same synteny as the human gene and the resultant protein has 70% 
amino acid sequence identity with the hP2Y11 receptor. An amphibian p2y receptor (AM040941) 
that has 35% amino acid sequence identity with the hP2Y11 receptor is proposed to be the species 
homologue of Xenopus [10]. Putative orthologues are identified in a number of other species in the 
NCBI HomoloGene database, but intriguingly, the gene does not appear where expected in the rat 
and mouse genomes and convincing P2RY11 mRNA transcripts have not been identified in rodent 
tissues [2,11,12]. Furthermore, it is unlikely that the gene has translocated to a different 
chromosomal region and can still be transcribed to produce a functional protein, as using the human 
sequence to search the UniProt protein database for similar mouse proteins, Dreisig and Kornum, 
[12] found the closest match to be the P2Y1 receptor, at 32% similarity. This is the same degree of 
similarity as seen between the human P2Y1 and P2Y11 receptors (Table 1). Thus there is no 
evidence for expression of P2RY11 mRNA and P2Y11 protein in rodents that resemble those present 
in humans, which must be taken into account when considering pharmacological studies in rodent 
tissues, as will be discussed below. 
 
3. Coupling of P2Y11 receptors to 2nd messenger systems  
Direct activation of signalling pathways As P2Y receptors are GPCR, they couple to heterotrimeric 
G proteins and in this respect they fall into two groups: the P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 
subtypes couple mainly to GDq/11, as indicated by a rise in cytoplasmic levels of inositol 1,4,5-
trisphosphate (IP3) and related inositol phosphates (IPs), whilst the P2Y12, P2Y13 and P2Y14 
receptors couple to GDi/o [2,13]. The P2Y11 receptor is unique in that it couples to both GDq/11 and 
GDs [14]. When activated, GDq/11 stimulates PLCE, which cleaves phosphatidylinositol 4,5-
bisphosphate in the plasma membrane into 1) IP3, which binds to IP3 receptors in the endoplasmic 
reticulum to release Ca2+ stores; and 2) diacylglycerol, which activates protein kinase C (PKC). GDq 
can also bind to and activate the guanine nucleotide exchange factor, p63RhoGEF, which in turn 
stimulates Rho GTPases, such as RhoA [15]. GDs, on the other hand, activates adenylyl cyclase, 
leading to increased synthesis of cAMP and subsequently stimulation of protein kinase A. 
 Initially, ATP was reported to activate adenylyl cyclase with similar [6] or greater potency 
[14] compared to PLC activation. The experiments were, however, carried out in different cell lines; 
1321N1 human astrocytoma cells for IP accumulation and CHO-K1 cells for cAMP synthesis. 
Since agonist potency is greatly influenced by the level of receptor expression [16,17], the coupling 
of the hP2Y11 receptor to these signalling pathways was studied further in the same cell line [18]. In 
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1321N1 cells, ATP promoted IP accumulation with low µM potency (EC50 = 8.5 ± 0.1 µM) and was 
15-fold less potent in raising cAMP (EC50 =130 ± 10 µM). In CHO-K1 cells, ATP evoked IP 
accumulation with slightly higher potency (EC50 = 3.6 ± 1.3 µM) than in 1321N1 cells, but it was 
still 15-fold less potent in promoting cAMP synthesis (EC50 = 62.4 ± 15.6 µM). Comparable 
differences in potencies for promoting the two second messenger responses were observed with 
other adenosine nucleotide analogues. Thus the P2Y11 receptor appears to couple more effectively 
with the GDq/11 signalling pathway than that of GDs. 
 
Indirect activation of adenylyl cyclase It is important to note that some isoforms of adenylyl 
cyclase can be activated by PKC, independently of GDs [19]. For example, P2Y1 receptors can 
activate PKCȗZKLFKLQFUHDVHVWKHDFWLYLW\RILVRIRUPRIDGHQ\O\OF\FODVH[20]. Such a 
mechanism does not appear to underlie the rise in cAMP mediated by P2Y11 receptors, as inhibition 
of PKC did not supress cAMP production elicited by stimulation of the canine P2Y11 (cP2Y11) 
receptor stably expressed in CF2Th cells [9]. Concomitant activation of PKC may, however, 
potentiate cAMP synthesis, as down-regulating PKC by chronic treatment with a phorbol ester 
decreased ATP-promoted cAMP accumulation by 60-80%, with no chDQJHLQ$73¶VSRWHQF\, in 
both 1321N1 and CHO-K1 cells expressing the hP2Y11 receptor [18]. Likewise, chelation of 
intracellular Ca2+ decreased ATP-promoted cAMP accumulation by ~45% in 1321N1 cells, whereas 
chelation had no effect on either the efficacy or potency of ATP in CHO-K1 cells. Thus the capacity 
of the P2Y11 receptor to elicit cAMP accumulation appears to be via GDs, and this can be 
potentiated by the concomitant activation of PKC and mobilisation of intracellular Ca2+ stores in a 
cell-type- and/or species subtype-dependent manner. 
  
4. Pharmacological properties of P2Y11 receptors 
Agonists The hP2Y11 receptor is adenine nucleotide-preferring, with ATP more potent than ADP, 
whilst UTP, UDP and the nucleotide triphosphates, guanosine 5'-triphosphate (GTP), cytidine 5'-
triphosphate, thymidine 5'-triphosphate and inosine 5'-triphosphate (ITP), are inactive [6,18,21]. 
The rank order of agonist potency for increasing either cAMP or IPs is ARC67085MX  t ATPJS | 
BzATP > dATP > ATP | 2-methythioATP | ATPĮS > $'3ȕ6!-methylthioADP > ADP 
[6,14,18,22,23,24]. ,QDGGLWLRQWKHGLSKRVSKDWHV$'3$'3ȕ6DQG-methylthioADP are partial 
agonists, with apparent efficacies of 60-80% of maximal response to ATP [23]. Note that AR-
C67085XX, the most potent P2Y11 agonist, also antagonises P2Y12 receptors [13], which limits its 
usefulness in characterising the functions of native P2Y11 receptors. These studies all used the 
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original hP2Y11 clone, in which the N terminal amino acid sequence begins MDR. When the 
receptor with the correct sequence, MAANVS, was expressed, there was, however, no significant 
difference in the potency of ATP and related molecules between the two isoforms [24].  
 Screening of a library of sulphonic and phosphonic acid derivatives identified NF546, a full 
agonist at hP2Y11 receptors [24]. It is 2.5-fold less potent than ATP, but has a degree of selectivity 
over other P2Y subtypes as its EC50 value at hP2Y11 receptors was 28-fold, 102-fold and 604-fold 
lower than that at human P2Y2, P2Y6 and P2Y12 receptors respectively and it had little or no effect 
at human P2Y1 and P2Y4 receptors. Its activity at other P2X and P2Y subtypes has not been 
reported. Apparent agonist potency in bioassays depends, however, on the level of receptor 
expression, so whilst NF546 is a very useful tool for the pharmacological characterisation of native 
P2Y receptor subtypes, an action over a particular concentration range is not necessarily evidence 
for the presence of P2Y11 receptors and an appropriate antagonist action profile and/or knockdown 
of the receptor using siRNA must also be obtained. 
 Nicotinamide adenine dinucleotide (NAD+) and nicotinic acid adenine dinucleotide phosphate 
(NAADP+), which both play important roles in intracellular signalling, are also hP2Y11 agonists 
[25,26]. Furthermore, it has been suggested that NAD+ can be released from cells via connexin 43 
hemichannels and so may act endogenously [27]. Note, however, that NAD+ also stimulates other 
P2 subtypes, including P2X1, P2X4, P2X7 and P2Y1 receptors [28,29]. In addition, NAD
+ can be 
metabolised to cyclic ADP-ribose, a potent agonist for release of intracellular Ca2+ stores [30], so a 
pharmacological effect of NAD+ cannot, on its own, be automatically taken as evidence for the 
expression of P2Y11 receptors and again and an appropriate antagonist action profile and/or 
knockdown of the receptor using siRNA must also be obtained. 
  
Antagonists Suramin and PPADS are general, non-selective P2X and P2Y antagonists [5,31] 
and whilst suramin, at low µM concentrations, is a surmountable hP2Y11 antagonist, PPADS is 
inactive [14,22]. The suramin analogue, NF157, is a competitive antagonist with pA2 = 7.77, which 
makes it more potent than suramin, and it is at least 650-fold selective over P2Y1 and P2Y2 
receptors [32]. In addition, NF157 is non-selective over P2X1 receptors and has low (P2X2, P2X3) 
to moderate (P2X4, P2X7) selectivity over other P2X subtypes [32]. Its activity at other P2X and 
P2Y subtypes has not been reported. These factors can limit its usefulness when studying native 
P2Y11 receptors and care must be taken when using NF157 to obtain supporting data, such as lack 
of effect of a range of other P2X and P2Y antagonists and/or depression of receptor expression 
using tools such as siRNA. 
 Another suramin analogue, NF340, is also a competitive antagonist, with a pA2 of 8.02 [24]. 
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10 µM NF340 inhibited responses at recombinant human P2Y1, P2Y2, P2Y4 and P2Y6 receptors by 
less than 10% and so NF340 was calculated to have at least 520-fold selectivity over other P2Y 
receptors. Similarly, stimulation of recombinant human P2X1, P2X2 and P2X2/3 receptors was 
unaffected by 3 µM NF340. This compound may, therefore be more useful in determining the 
physiological functions of native P2Y11 receptors, but again, its activity at other P2X and P2Y 
subtypes has not been reported and supporting data should be obtained.  
 
UTP is not a biased agonist at P2Y11 receptors  Biased agonism describes a multi-state model of 
GPCR activation in which each ligand induces a unique structural conformation of the receptor, 
such that the receptor couples differentially to G proteins and other intracellular proteins. For 
example, activation of the P2Y2 UHFHSWRUE\873FDXVHVVLPLODUWUDQVORFDWLRQRIȕ-arrestin-1 and 2 
from the cytoplasm to the plasma membrane, whereas ATP induced a greater translocation of ȕ-
arrestin-1 [33]. These differential effects of ATP and UTP had a downstream effect on cell 
signalling, as both agonists increased the levels of phosphorylated extracellular-signal regulated 
kinase, but the effect of UTP was transient, whereas that of ATP was prolonged.  
 As discussed above, all of the initial studies found UTP to be ineffective at raising IPs or 
cAMP in cells expressing hP2Y11 receptors. A subsequent report proposed, however, that UTP was 
a biased P2Y11 agonist, as it increased cytosolic [Ca
2+], but did not induce accumulation of IPs, 
whereas ATP did both [34]. This was an intriguing proposal, so we studied the action of UTP at 
P2Y11 receptors in greater detail [21].  
 We found that ATP evoked a rapid, concentration-dependent rise in intracellular Ca2+ with an 
EC50 that was essentially the same as that reported by [34]. This is not surprising, as the 1312N1-
hP2Y11 cell line used in both studies was generated by the present author whilst on sabbatical at the 
University of North Carolina. Despite this, we did not observe a rise in intracellular Ca2+ when UTP 
was applied, even at 100 µM, a concentration that was almost maximally effective in the earlier 
study (Figure 1). Consistent with this, another group also failed to see a UTP-induced rise in 
intracellular Ca2+ levels in 1321N1 cells stably expressing the hP2Y11 receptor [24]. Furthermore, 
we found that coapplying a high concentration of UTP with ATP did not inhibit either the rise in 
Ca2+ or IPs evoked by ATP (Figure 2), indicating that UTP does not bind to this receptor. 
 In contrast, UTP was slightly, but significantly more potent than ATP in evoking a rise in 
intracellular Ca2+ in 1321N1 cells stably expressing the human P2Y2 receptor, with no difference in 
the maximum response. Thus the lack of response to UTP at hP2Y11 receptors was not due to a 
problem with the UTP solution. So, contrary to the previous report, we found no evidence for an 
agonist action of UTP at the hP2Y11 receptor, nor does UTP act as an antagonist. In our view the 
 8 
most feasible explanation for the discrepancy in the activity of UTP is contamination of the UTP 
solution by a non-nucleotide agent acting at a receptor that is not a P2Y receptor in the earlier study. 
 
cP2Y11 pharmacology Interestingly, the cP2Y11 receptor is adenine diphosphate-preferring, with 
reported rank order of agonist potencies of $'3ȕ6 -methylthioADP  | 2-methylthioATP >> 
ADP > ATP [9] and 2-PHWK\OWKLR$'3!$'3ȕ6!-methylthioATP > ADP > $73Ȗ6t ATP [23] 
for both IP and cAMP production. Furthermore$'3$'3ȕ6DQG-methylthioADP are full 
agonists [23]. Like the hP2Y11 receptor, UTP, UDP, GTP and ITP were inactive, and suramin, but 
not PPADS inhibited these responses. 
 The human and canine receptors have only 70% amino acid identity and a mutagenesis study 
targeted the arginine residue (Arg268) that is present at the junction between TM6 and the third 
extracellular loop of the hP2Y11 receptor, by replacing it with glutamine, which is present in the 
analogous position in the cP2Y11 receptor [23]. This change increased both the potency and efficacy 
of ADP relative to ATP, such that they were now nearly equipotent and equi-efficacious. Likewise, 
mutating the glutamine in the canine receptor to arginine increased the efficacy and potency of ATP 
relative to ADP, and they now had essentially identical potency and efficacy. Thus this single 
amino acid within the P2Y11 receptor is at least partially responsible for the species differences in 
its pharmacological properties.  
 
Ligand binding site Computational modelling and mutational analysis have provided insight to 
some of the amino acid residues that likely play a role in ligand binding. As noted above, Arg268 in 
the hP2Y11 receptor is at least partially responsible for the differences in the relative potency of 
ATP and ADP compared with at the canine orthologue [23]. This amino acid also plays a major role 
in agonist stereo-selectivity. The hP2Y11 receptor is preferentially activated by the Rp stereoisomer 
RI$73Į6EXWPXWDWLQJArg268 to an uncharged residue caused the stereo-selectivity to be lost 
[35]. This mutational approach has also implicated arginine 106 and 307, glutamate 168 and alanine 
313 in the ATP binding pocket [36]. Determination the three dimensional structure of the P2Y11 
receptor through crystallisation or similar high resolution techniques is required, however, to 
confirm this. 
 
5. P2Y1/P2Y11 heteromultimers  
GPCR were long considered to be monomeric entities that couple to G proteins on a 1:1 
stoichiometric basis. It is now clear, however, that GPCR, including P2Y receptors, can interact to 
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form dimeric or higher ordered oligomeric complexes, which may couple to one or more G 
proteins, with implications for the regulation of receptor subcellular localisation and trafficking, 
ligand binding and functional activity [37-40]. Constitutive formation of P2Y1, P2Y4, P2Y6 and 
P2Y12 homodimers has been shown using biochemical techniques [41,42,43] and publication of the 
crystal structure of the P2Y12 receptor confirmed the latter [44]. Furthermore, different P2Y 
subtypes can interact physically to form function heterodimers, with altered pharmacological and 
signalling properties (see, for example, [45,46,47].  
 This is true also for the P2Y11 receptor, which forms a complex with P2Y1 receptor that has a 
greatly altered sensitivity to the antagonists, MRS2179 and NF157 [48]. In addition, the P2Y11 
receptor did not undergo agonist-induced endocytosis when expressed on its own, consistent with 
the early report that P2Y11 receptors do not desensitise [14]. However, after cotransfection of the 
P2Y1 subtype, ATP induced endocytosis of the P2Y11 protein, which was not inhibited by the P2Y11 
antagonist NF157 [48]. The authors, therefore, concluded that agonist-induced endocytosis of the 
P2Y11 receptor requires coexpression of the P2Y1 receptor and in a subsequent study identified 
alanine 87 of the P2Y11 receptor as playing a crucial role in the interaction with P2Y1 receptors 
[49]. In addition, G protein receptor kinase 2 may also be required for P2Y11 internalisation [33]. 
 
6. Expression of P2Y11receptors 
mRNA expression Many studies using RT-PCR or northern blotting have reported detection of 
P2RY11 mRNA in a range of tissues and species [2], but this is complicated by the discovery that 
the P2RY11/PPAN fusion mRNA transcript is expressed widely (see [12] for an extensive 
overview). The latter transcript comprises the second exon of P2RY11 and most of the sequence of 
PPAN, so RT-PCR and northern blotting will only distinguish between the two sequences if one of 
the primers is designed to recognise at least part of the first exon of P2RY11 and/or part of the 
untranslated upstream sequence.  
 After a detailed and extensive review of the published literature, Dreisig and Kornum [12] 
identified only 5 papers out of 89 in which detection of the fusion transcript could confidently be 
discounted, all in human cells [50-54]. Thus it is clear that care must be taken when designing 
primers and that many reports that claimed to show P2RY11 mRNA expression need to be revisited 
and reviewed. The same group subsequently reported detection of P2RY11 mRNA in distinct 
regions of macaque monkey brain [55]. 
 
Protein expression The presence of mRNA may not necessarily mean that the corresponding 
protein is expressed, so it is essential to confirm protein expression using a selective antibody. This 
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approach has been used widely to study expression of all P2Y receptor subtypes, but in most cases 
the specificity of the antibody has not been unequivocally confirmed, for example, by showing that 
staining is absent in the appropriate receptor knock-out animal. Indeed, a commonly-used anti-P2Y1 
antibody has been reported to be nonspecific [56] and we found that several commercially-available 
P2Y subtype antibodies show staining in 1321N1 cells, which do not express endogenous P2Y 
receptors (Kennedy, unpublished observations). Thus care must be taken when interpreting 
antibody staining data. 
 This holds true for data obtained using anti-P2Y11 antibodies, as a review of the published 
literature identified several issues with the commercially-available anti-P2Y11 antibodies [12]. Most 
of these target a region of the C-terminus of the receptor that has significant sequence similarity 
with the C-terminus of other P2Y subtypes, so there is a reasonable chance that this antibody may 
not be specific for the P2Y11 receptor. Although the predicted size of the P2Y11 protein is 40 kDa, 
western blot data from different groups, in which the most commonly used antibody (#APR-015) 
was utilised, reported the molecular mass to be 33-60 kDa. All claimed that their band represented 
the monomeric P2Y11 receptor (see [12] for full details).  
 Anti-P2Y11 antibodies also bind proteins in rodent tissues [2,12], even though the P2RY11 
gene is not present in the rodent genome, further casting doubt upon their specificity. An attempt to 
verify the specificity of three commercially-available anti-P2Y11 antibodies was made by first 
determining if they recognised the recombinant hP2Y11 receptor when expressed in a cell line [55]. 
One antibody that targeted the 3rd cytoplasmic loop of the hP2Y11 receptor did not show any signal 
of the expected band size in western blots, but instead produced two bands of 142 and 195 kDa, 
including in untransfected cells. The other two antibodies, targeted against the 3rd extracellular loop 
or the C-terminus, both produced multiple bands, including of the expected size. These two 
antibodies stained neuronal-like cells in macaque monkey brain, but an identical staining pattern 
was also seen in rat brain. Thus the specificity of these antibodies could not be validated. 
 Finally, the targeted C-terminus region is also present in the P2Y11/PPAN fusion protein, 
which has a predicted size of 90 kDa, so that too will be detected by anti-P2Y11 antibodies. For 
example, an antibody generated against a sequence at the end of the P2Y11 C-terminus produced a 
band of around 90 kDa in western blots using CHO-K1 cells transfected with the P2RY11/PPAN 
fusion plasmid, whereas transfection with the P2RY11 plasmid resulted in bands of around 45 kDa 
[7]. Transfection with the empty vector produced no bands. 
 
7. Functions of P2Y11receptors 
Criteria for identifying receptor function  Ideally, a comprehensive understanding of the 
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function of any receptor arises from characterisation of the effects of highly selective agonists and 
antagonists on cellular and tissue activity and correlation of these with the expression of its mRNA 
and protein and perhaps also with the effects of deleting the gene or supressing translation of the 
mRNA. Unfortunately, since the P2RY11 gene appears to be absent in mice and rats, the species 
used in genetic deletion studies, it is not possible to produce P2Y11-knock-out animals. In addition, 
as discussed above, doubt has been cast on the specificity of commercially-available anti-P2Y11 
antibodies. Nonetheless, possible functions of native P2Y11 receptors have been identified in a 
range of non-rodent cells by applying two or more of the following criteria: a) detection of mRNA 
using appropriately designed primers; b) demonstration of appropriate effects of appropriate 
concentrations of NF546, NF157 and NF340; c) lack of effect of agonists and antagonists selective 
at other P2Y and P2X subtypes; d) inhibition of the proposed P2Y11 function by P2RY11 RNA 
interference. Detection of a band close to the predicted size of the P2Y11 receptor, ~40 kDa, in 
western blots, although not direct evidence in itself, might also be considered consistent with P2Y11 
expression in a tissue.  
 Mostly, the proposed functions are based on single reports, though they may be supported by 
other studies in the same cell type in which only one of the above criteria are fulfilled. The majority 
of studies used siRNA knock-down of hP2Y11 receptors to support pharmacological data and many 
are in blood cells involved in immune responses, consistent with extracellular ATP being a member 
of the damage-associated molecular patterns (DAMPs) family [57]. 
 
Granulocytes ȕ-NAD+ elicited rises in cytoplasmic Ca2+, IP3 and cAMP in freshly isolated 
human granulocytes, which were inhibited by 1 µM NF157, (a concentration that is 50-times higher 
than the antagonist¶s affinity for hP2Y11 receptors) and downregulation of P2Y11 expression by 
siRNA [25]. )XUWKHUPRUH1)LQKLELWHGȕ-NAD+-induced granulocyte chemotaxisand it was 
suggested that ȕ-NAD+ is an endogenous hP2Y11 agonist and acts as a proinflammatory cytokine. 
Subsequently, similar effects were seen with another endogenous P2Y11 agonist, NAADP
+ [26]. 
 
Neutrophils Human neutrophils undergo constitutive apoptosis, which was delayed by ATP, 
NAD+ and BzATP, but not UTP and appeared to be dependent upon cAMP activation of PKA [58], 
consistent with earlier reports of a P2Y11-mediated increase in cAMP in human HL-60 cells, which 
are comprised mainly of neutrophil promyelocyte precursor cells [59,60]. The delay in apoptosis 
was inhibited by 500 nM NF157, but unaffected by P2X7 antagonism. Western blotting identified a 
protein of approximately 45 kDa. Similar results were reported in [61], which further demonstrated 
that the delay in neutrophil apoptosis was due to inhibition of the mitochondrial, but not the 
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extrinsic, pathway of apoptosis. Thus endogenous ATP, and possibly also NAD+, may act via P2Y11 
receptors to increase neutrophil survival, which will prolong the inflammatory response and the 
ability of neutrophils to phagocytose and destroy foreign particles and invading microorganisms. 
Further supporting evidence is, however, required. 
 
Macrophages THP-1 cells are a human acute monocytic leukemia cell line that differentiate into 
the M1-proinflammatory type of macrophage after priming with lipopolysaccharide (LPS) and 
interferon-J. This was inhibited by apyrase, a soluble enzyme that dephosphorylates ATP, and by 50 
µM NF157 [62]. This is a high concentration of NF157 (2,500-times greater than its KB at P2Y11 
receptors) and is enough to produce substantial blockade of numerous P2X and P2Y subtypes. 
THP-1 differentiation, was, however, unaffected by a range of other antagonists, PPADS (non-
selective P2X and P2Y antagonist), NF449 (P2X1 antagonist), A438079 (P2X7 antagonist), 
MRS2179 (P2Y1 antagonist), MRS2578 (P2Y6 antagonist), clopidogrel (P2Y12 antagonist), 
MRS2211 (P2Y13 antagonist), consistent with NF157 acting here via P2Y11 receptors. Furthermore, 
THP-1 differentiation was also supressed by down-regulation of P2Y11 receptors by specific siRNA.  
 LPS also induced the release of the pro-inflammatory cytokine, IL-6, and this too was 
inhibited by NF157 and P2Y11-specific siRNA. Inhibition of adenylyl cyclase, similarly, depressed 
IL-6 release, consistent with IL-6 release being mediated by P2Y11 receptors. Based on these and 
other results, the authors concluded that LPS induces vesicular exocytosis of ATP from macrophage 
precursor cells, which then acts in an autocrine manner at P2Y11 receptors to cause these cells to 
differentiate into M1-pro-inflammatory macrophages that release pro-inflammatory cytokines, such 
as IL-6. In addition, they proposed that P2Y11 receptor antagonists might potentially be useful in the 
treatment of inflammatory diseases, such as sepsis. 
 
Dendritic cells  The first clear evidence for functional expression of P2Y11 receptors in human 
dendritic cells was that the P2Y11 agonist, NF546, induced a rise in intracellular Ca
2+ concentration 
that was abolished by NF340 [24], which is consistent with expression of P2RY11 mRNA in these 
cells [51].  In contrast to the studies above, which indicate pro-inflammatory roles for P2Y11 
receptors, an anti-inflammatory role is indicated in human cultured, monocyte-derived dendritic 
cells [63]. Here, ATP and BzATP, but not ADP, UTP or UDP, induced dendritic cell maturation, 
which was inhibited by 10 µM NF340 and suramin, but unaffected by PPADS and P2X4 and P2X7 
antagonists. In these cells, LPS caused release of the inflammatory cytokine, IL-12 and this was 
inhibited by ATP, an action that was reversed by both NF340 and down-regulation of P2Y11 
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receptors by specific siRNA. Exposing dendritic cells to hypoxia for 5 hours, followed by 
reoxygenation, also suppressed the inhibitory effects of ATP and in addition, down-regulated 
P2RY11 mRNA. The authors proposed that this inhibition of P2Y11 receptor activity may cause 
dendritic cells to become pro-inflammatory and so contribute to post ischaemia/reperfusion injury. 
 
Bronchial epithelial cells The human bronchial epithelial cell lines, NuLi-1 and CuFi-1, are 
amongst the small number of cell types in which expression of P2RY11 mRNA has been 
demonstrated with confidence [53]. This group further showed that in these cells, lipoxin A4 
(LXA4), a regulator of adaptive immunity that has been proposed to reduce inflammation, acts by 
inducing ATP release, which in turn stimulates P2Y11 receptors.  In these cells, LXA4 raised 
cytoplasmic Ca2+ and cAMP, increased airway surface liquid height, induced cell proliferation and 
migration and improved wound repair, all of which were inhibited by NF340 (0.1-1 µM). In 
addition, knock-down of the P2Y11 receptor using siRNA inhibited the increase in airway surface 
liquid height. Thus in this situation it is stimulation, rather than inhibition, of P2Y11 receptors that is 
likely to be beneficial therapeutically. 
 
Keratinocytes P2Y11 receptor-mediated release of pro-inflammatory cytokines is also indicated 
in keratinocytes [64]. Interferon-J induced IL-6 release from the human HaCaT keratinocyte cell 
line and this was inhibited by apyrase, suramin and NF157. The concentration of NF157 used, 100 
µM, was very high, but IL-6 release was unaffected by a range of other antagonists; PPADS (non-
selective P2X and P2Y antagonist), AZ10606120 (P2X7 antagonist), MRS2179 (P2Y1 antagonist), 
MRS2578 (P2Y6 antagonist), clopidogrel (P2Y12 antagonist), MRS2211 (P2Y13 antagonist). 
Furthermore, IL-6 release was also inhibited by down-regulation of P2Y11 receptors using specific 
siRNA. Thus P2Y11 receptors may play a role in inflammatory conditions of the skin, such as 
psoriasis and blocking them could facilitate skin repair. 
 
Mesenchymal cells NAD+ evoked rises in cytoplasmic Ca2+, cAMP and cyclic ADP-ribose in 
human bone marrow-derived mesenchymal stem cells, which were all abolished by 1 µM NF157 
[27]. Although alternative antagonists were not employed to rule out the involvement of other P2X 
and P2Y receptor subtypes, the effects of NAD+ were also inhibited by P2Y11 receptor down-
regulation by siRNA, consistent with NAD+ acting here via P2Y11 receptors. In the same study, 
NAD+ also induced NF157-sensitive chemotaxis of the mesenchymal cells, a small increase in cell 
proliferation, release of a variety of cytokines and increased nuclear translocation of a number of 
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cAMP/Ca2+-dependent transcription factors. The cells also released NAD+ and ATP via connexin43 
hemi-channels, suggesting that these nucleotides may act as endogenous modulators of 
mesenchymal cell function. 
 
8. P2RY11 polymorphisms as an indicator of function Numerous SNPs of the P2RY11 gene are 
identified in the NCBI Single Nucleotide Polymorphism database and whilst their functional 
consequences are mostly unknown, genetic screening has implicated two SNPs in disease states. 
 
Cardiovascular disease  Genotyping of participants in the Malmo Diet and Cancer (MDC) 
study identified a small increased risk of acute myocardial infarction (AMI) in the A87T 
polymorphism (rs3745601) and the risk was greater in patients with a family history of AMI and/or 
early onset AMI [65]. In addition, patients in the MDC cardiovascular risk group had elevated 
plasma levels of C-reactive protein, a marker of inflammation and a strong prognostic factor for the 
development of AMI. Thus this P2Y11 polymorph appears to be associated with increased systemic 
inflammation and risk of cardiovascular disease. 
 Position 87 is near the extracellular end of the second transmembrane spanning region of the 
P2Y11 receptor and the P2Y11A87T variant replaces a hydrophobic alanine residue with a polar 
threonine. How this could lead to the changes seen in the MDC cohort is unclear, but the A87T 
mutation had no effect on the potency and efficacy of BzATP compared with wild-type P2Y11 
receptors expressed on their own, but BzATP became inactive when hP2Y11A87T was coexpressed 
with P2Y1 receptors [49]. This was not mimicked by replacing A87 with serine or tyrosine. 
Additionally, the A87T mutation rendered the receptor insensitive to agonist-induced internalisation 
and the authors concluded that it disrupts the P2Y1/P2Y11 heteromeric receptor interaction. 
 
Narcolepsy  Increasing evidence indicates that narcolepsy is an autoimmune disease that leads 
to a loss of hypocretin (orexin)-releasing neurones in the hypothalamus. Genome-wide association 
studies have identified a SNP (rs2305795) that is associated with narcolepsy in European and Asian 
[51], Chinese [66] and Japanese [67] patients. The SNP is in a region RIWKHƍXQWUDQVODWHG
sequence of P2RY11 that appears to regulate transcription, as it correlated with substantially 
reduced expression of P2RY11 mRNA in CD8+ T lymphocytes and natural killer cells of the 
carriers, which in turn was associated with a reduced ability of P2Y11 receptors to inhibit ATP-
induced monocyte cell death [51]. These data are consistent with roles for P2Y11 receptors in 
modulation of immune cell function, as discussed above. 
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9. P2Y11-like receptors in rodents As discussed in section 2, the P2RY11 gene has not been 
identified in rodent genomes and careful analysis has failed to reveal good evidence for expression 
of P2RY11 mRNA and P2Y11 protein in rodents that resemble those present in humans. 
Nonetheless, there is a body of reports that propose functional P2Y11 receptor expression in rodent 
tissues. Some are based on the ability of ATP to raise cytosolic cAMP, but, as discussed in section 
3, some isoforms of adenylyl cyclase can be activated independently of GDs and so an increase in 
cAMP cannot, on its own, be taken as evidence for P2Y11 expression. In the main, the reports are 
based on pharmacological data using agonists, such as NAD+, and/or NF157, as a supposedly 
selective P2Y11 antagonist. As discussed in section 4, however, both compounds have multiple sites 
of action and should not EHGHVFULEHGDV³VHOHFWLYH´)XUWKHUPRUHQRUHSRUWKDVFRQYLQFLQJO\
excluded these other sites from the effects of NAD+ or NF157 by using a variety of subtype-
selective antagonists. In addition, data obtained using NF340 or NF546, which are more selective 
that NAD+ and NF157, cannot be supported by knock-down of the receptor by siRNA due to the 
lack of the P2RY11 gene. Consequently, until a solution to the apparent lack of P2RY11 gene in 
rodent genomes has been found, these receptors should, at best, only be termed P2Y11-like. 
 
10. Concluding remarks In the 20 years since the P2Y11 receptor was first cloned, our 
knowledge and understanding of its properties and functions have improved relatively slowly. This 
has been, in part, due to its apparent absence in mice and rats, the most commonly used species for 
studying receptors and drug action and which prevent genetic deletion studies from being 
performed. In common with many other purinergic receptor subtypes, progress has also been 
hampered by the limited range of selective pharmacological tools. Nonetheless, by careful use of 
the available tools, along with suppression of receptor expression using siRNA and also genetic 
screening for SNPs, possible functions of native P2Y11 receptors have been identified in a range of 
human cells and tissues. Many are in blood cells involved in inflammatory responses, consistent 
with extracellular ATP being a DAMP signalling molecule in the immune system. Thus proposed 
potential therapeutic applications relate, in the main, to modulation of acute and chronic 
inflammatory responses. Further study of these in animals will require the development of non-
rodent models, whilst selective ligands with suitable pharmacokinetic properties are needed before 
potential trials in humans can go ahead. Regardless of these difficulties it is clear that the P2Y11 
receptor is a viable, novel therapeutic target. 
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% identity 
Subtype P2Y1 P2Y2 P2Y4 P2Y6 P2Y11 P2Y12 P2Y13 P2Y14 
P2Y1 - 38 44 46 32 24 24 27 
P2Y2  - 41 41 29 25 26 26 
P2Y4   - 43 32 25 26 28 
P2Y6    - 34 24 24 23 
P2Y11     - 22 21 23 
P2Y12      - 48 48 
P2Y13       - 47 
P2Y14        - 
 
Table 1. Human P2Y receptor subtype amino acid sequence identity 
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Figure Legends 
Figure 1. ATP, but not UTP increases intracellular Ca2+ in 1321N1-hP2Y11 cells. 
a) The superimposed traces show fluo-4 fluorescence dXULQJVXSHUIXVLRQZLWK$73ȝ0XSSHU
WUDFHDQG873ȝ0ORZHUWUDFHIRU90 sec, as indicated by the horizontal bar. Both records 
are from the same population of cells. b) The mean peak amplitude of responses evoked by ATP 
Q DQG873ȝ0Q DQGȝ0Q DUHVKRZQ5HVSRQVHVDUHH[SUHVVHGDVRIthe 
UHVSRQVHWR$73ȝ0. Vertical lines show S.E.M. From Morrow et al., (2014). 
 
Figure 2.  UTP does not inhibit ATP-evoked responses in 1321N1-hP2Y11 cells. 
a) The traces show the rise in intracellular Ca2+ evoked by $73ȝ0in the same population of 
cells before (left-hand side) and after superfusion for 10 min with UTP ȝ0right-hand side), 
as indicated by the horizontal bars. b) The mean peak amplitude of responses evoked by ATP (2 
ȝ0in the absence and presence of UTP (100 ȝ0Q 5) are shown. Responses are expressed as % 
of the control response to ATP (2 ȝ0c) The mean basal level of IPs (left-hand column) and the 
PHDQDPSOLWXGHRIUHVSRQVHVHYRNHGE\$73ȝ0LQWKHDEVHQFHPLGGOHFROXPQDQGSUHVHQFH
RI873ȝ0ULJKW-hand column) are shown. n=3. Vertical lines indicate S.E.M. From Morrow 
et al., (2014). 
